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ABSTRACT
PURPOSE: To investigate the effects of pentoxifylline (PTX) in experimental acute pancreatitis (AP) starting drug administration after 
the induction of the disease. 
METHODS: One hundred male Wistar rats were submitted to taurocholate-induced AP and divided into three groups: Group Sham: 
sham-operated rats, Group Saline: AP plus saline solution, and Group PTX: AP plus PTX. Saline solution and PTX were administered 
1 hour after induction of AP. At 3 hours after AP induction, peritoneal levels of tumor necrosis factor (TNF)-α, and serum levels 
of interleukin (IL)-6 and IL-10 levels were assayed by Enzyme-Linked Immunosorbent Assay (ELISA). Determinations of lung 
myeloperoxidase activity (MPO), histological analysis of lung and pancreas, and mortality study were performed. 
RESULTS: PTX administration 1 hour after induction of AP caused a significant decrease in peritoneal levels of TNF-α and in serum 
levels of IL-6 and IL-10 when compared to the saline group. There were no differences in lung MPO activity between the two groups 
with AP. A decrease in mortality was observed in the PTX treatment compared to the saline group. 
CONCLUSIONS: Administration of PTX after the onset of AP decreased the systemic levels of proinflammatory cytokines, raising the 
possibility that there is an early therapeutic window for PTX after the initiation of AP.
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RESUMO
OBJETIVO: Investigar os efeitos da pentoxifilina (PTX) na pancreatite aguda (PA) experimental administrando a droga após a indução 
da doença.
MÉTODOS: Cem ratos machos Wistar foram submetidos à indução da PA através da infusão de taurocolato de sódio e divididos em 
três grupos: Grupo Sham: sham-operated ratos, Grupo Salina: AP e solução salina, e Grupo PTX: AP e PTX. Solução salina e PTX 
foram administradas 1 hora após a indução da PA. Três horas após indução da PA os níveis de fator de necrose tumoral (TNF)-α no 
líquido peritoneal e os níveis séricos de interleucina (IL)-6 e IL-10 foram analisados pelo método de Enzima Imunoensaio (ELISA). A 
atividade da mieloperoxidase (MPO) foi analisada no pulmão e foram realizadas análises histológicas do pulmão e pâncreas, além do 
estudo da mortalidade.
RESULTADOS: A administração de PTX 1 hora após a indução da PA reduziu significativamente os níveis de TNF-α peritoneal e os 
níveis séricos de IL-6 e IL-10 quando comparado ao grupo salina. Redução na mortalidade foi observado após o tratamento com PTX 
comparado ao grupo salina.
CONCLUSÃO: A administração de PTX após a indução da PA diminuiu os níveis sistêmicos de citocinas pró-inflamatórias, sugerindo 
a possibilidade de que existe uma janela terapêutica para PTX após o início do PA.
Descritores: Pancreatite Aguda; Pentoxifilina; Inflamação; Citocinas; Resposta Inflamatória Sistêmica
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Introduction
Severe acute pancreatitis (AP) is a disease related to 
high morbidity and mortality. It is associated with an increase in 
inflammatory mediators that induce the systemic inflammatory 
response syndrome (SIRS) and can lead to distant organ 
dysfunction1,2.
Serum levels of proinflammatory cytokines such as 
interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor (TNF)-α, 
platelet activating factor (PAF), and nitric oxide (NO) increase 
early during the course of AP and these levels directly correlate 
with the severity of pancreatic inflammation3. In addition, 
TNF-α, a cytokine produced mainly by activated monocytes and 
macrophages, seems to play an important role as a mediator of 
inflammation and cellular immune responses in AP through the 
initiation of a cytokine cascade4,5.
Administration of agents that antagonize or diminish 
the production of TNF-α is associated with a decrease of the 
systemic effects of AP6-10. Pentoxifylline (PTX), a methylxanthine 
derivative, exhibits marked anti-inflammatory properties through 
the inhibition of nuclear factor (NF)-κB and consequently blocks 
TNF-α production11-12.
Treatment of AP with PTX has shown to be beneficial 
in the experimental management of this disease13-16. Studies from 
our group have demonstrated that administration of PTX in rats 
with taurocholic acid-induced AP reduced local and systemic 
inflammatory responses and decreased pancreatic infection and 
mortality rate16. However, administration of this drug in these 
studies was done at the time of AP induction, which is unrealistic in 
a clinical setting where patients already have developed systemic 
inflammation. 
In the present study we attempt to elucidate the presence 
of an early therapeutic window for PTX as an anti-inflammatory 
drug after the onset of AP in an experimental animal model.
Methods
The experimental protocol was approved by the Ethics 
Commitee for Animal Research from the Medical School of São 
Paulo University. All animals received care in accordance with the 
Guide for the Care and Use of Laboratory.
One hundred adult male Wistar rats weighing 240 
to 260 g, housed in individual cages in a 12-hour dark light-
controlled environment, were used for the experimental protocol. 
Temperature was kept at 21 to 22oC and all rats were fed with a 
standard rat chow and ad libitum water. 
Reagents
All chemical reagents were purchased from Sigma-
Aldrich (St. Louis, MO). TNF-α, IL-6 and IL-10 were assayed 
with corresponding kits from BioSource International (Camarillo, 
LA, Calif).
Induction of acute pancreatitis
Surgical anesthesia was induced with ketamine chloride 
50 mg/ml (0.2ml/100g body weight) (Ketalar; Parke-Davis, São 
Paulo, Brazil). AP was induced in anesthetized rats by retrograde 
intraductal injection of 0.5 ml of 2.5% (w/v) sodium taurocholate 
in 0.9% (w/v) NaCl into the main pancreatic duct for 1 minute at 
a constant rate using an infusion pump (KD Scientific, Holliston, 
MA). The proximal part of the hepatic duct was clamped during 
the injection17,18.
Experimental groups
Animals were randomized to the following experimental 
groups:
Group Sham: twenty sham-operated rats submitted to 
operative procedure without induction of AP.
Group Saline: forty rats submitted to AP plus 
intraperitoneal administration of saline solution.
Group PTX: forty rats submitted to AP plus intraperitoneal 
administration of PTX. 
Pentoxifylline and saline administration
Intraperitoneal administration of PTX, at 25 mg/kg of 
animal weight (1.25 ml/Kg) (Trental™, Sanofi Aventis Pharma, 
São Paulo, Brazil), was performed one hour after induction of AP 
and the same dose was repeated after 12 hours.
Intraperitoneal administration of saline solution, at 1.25 
ml/kg of animal weight, was performed one hour after AP induction 
and was repeated after 12 hours. In previous experimental studies 
we have demonstrated that in this rat model of AP using sodium 
taurocholate the highest levels of inflammatory cytokines occurs 
between 2 and 4 h after AP induction therefore 1 hour is an 
appropriate length of time to start the treatment16.
Sample Preparation
At 3 hours after AP induction, animals were anesthetized 
for blood sampling through cardiac puncture and killed by 
exsanguination. Peritoneal levels of TNF-α and serum levels of 
IL-6 and IL-10 were assayed by a solid-phase sandwich enzyme-
linked immune absorbent assay (ELISA). Lung myeloperoxidase 
activity (MPO) was analyzed in lung homogenates. A portion of 
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the pancreas and lungs were fixed in 10% (v/v) buffered formalin 
for histological analysis.
Lung myeloperoxidase activity
MPO activity was used as an indicator of neutrophils 
infiltration into tissues. Samples of lung tissue were homogenized 
with a Polytron homogenizer using a homogenization buffer 
containing 0.5% of hexadecyltrimethyl ammonium bromide, 5 
mmol/L EDTA, and 50 mmol/L phosphate at pH 6.0. Homogenized 
samples were sonicated and centrifuged (3.000xg, 30 minutes) at 
4ºC. MPO activity in the supernatant was assayed by measuring 
the change in A460 resulting from the decomposition of H2O2 in 
the presence of O-dianisidine. Results were expressed as optical 
density (OD) at 460 mm19,20.
Histological analysis
Fragments of pancreas and lungs were harvested, fixed, 
embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin for light microscopy. Histological evaluation of the 
pancreas and lung sections was performed by the same pathologist 
in a blinded way.
Severity of necrotizing pancreatitis was determined by a 
scoring system that includes the graded assessment of pancreatic 
edema, inflammatory infiltration, pancreatic necrosis, pancreatic 
hemorrhage, and extrapancreatic fat necrosis, on a scale of 0 to 421. 
Lung injury was assessed using a 0 to 4 scoring system 
to evaluate the following lesions: intersticial cellular infiltration, 
intra-alveolar neutrophilic infiltration, intersticial and alveolar 
edema, hyaline membrane formation, capillary congestion, type II 
pneumocyte hyperplasia and intra-alveolar hemorrhage22.
Mortality study
Thirty animals from each group with AP were observed 
for a period of 7 days after AP induction to evaluate the mortality 
rate. These animals were maintained in individual cages with 
access to regular rat chow, and received PTX or saline solution as 
determined by the experimental protocol.
Statistical analysis
The groups were compared using ANOVA test and 
results are presented as mean values ± SEM. Histological analysis 
was performed by the Mann-Whitney test. Survival was evaluated 
using the Kaplan-Meier method and was analyzed for significance 
with the log-rank test (Cox-Mantel) and Wilcoxon test. The 
level of P<0.05 was considered statistically significant. The data 
were analyzed using Graphpad Prism® 4.0 software (San Diego, 
California).
Results
PTX effect on systemic inflammation in AP
We observed formation of ascitic fluid in the AP groups 
when compared with animals of the sham-operated group. PTX 
administration significantly reduced TNF-α levels in peritoneal 
fluid compared to the saline group (p=0.04) (Figure 1A).
\Levels of IL-6 and IL-10 were undetectable in the serum 
of sham-operated animals. A significant decrease in IL-6 (p=0.027) 
and IL-10 (p=0.037) levels was observed after PTX administration 
when compared to the saline group (Figures 1B and 1C).
Together, these data indicate a reduction of systemic 
inflammation after PTX administration in AP.
Coelho AMM et al.
490 - Acta Cirúrgica Brasileira - Vol. 27 (7) 2012
FIGURE 1:  Inflammatory  cytokines  levels  after AP  induction. AP 
was induced in rats by intraductal injection of 0.5ml of 2.5% taurocholic 
acid. Saline group received saline solution administration 1 hour after 
AP induction and PTX group received PTX treatment 1 hour after AP 
induction. Concentration of peritoneal TNF-α (A); serum IL-6 levels (B); 
and serum IL-10 (C). Data are expressed as mean ± SEM of 10 animals 
per group.   *p<0.05
Serum IL-6/IL-10 ratio
The serum IL-6/IL-10 ratio was calculated to determine 
possible imbalances in serum inflammatory activity. The serum 
IL-6/IL-10 ratios were 7.3 in saline AP rats, and 3.8 in AP rats 
treated with PTX. Accordingly, results indicated that there was 
a prevalence of anti-inflammatory activity in PTX treated rats 
compared with the saline group.
PTX effect on lung MPO activity
To assess lung inflammation by neutrophil infiltration, 
MPO activity was measured. At 3 hours after AP induction, MPO 
activity was increased in the pulmonary tissue. There was no 
statistical difference between the PTX and saline  treatments after 
AP induction (Figure 2). However, the results show a trend toward 
a reduction in lung inflammation in the PTX group (p=0.094). 
FIGURE 2: Myeloperoxidase activitiy in the lung after AP induction. 
AP was induced in rats by intraductal injection of 0.5ml of 2.5% 
taurocholic acid. Saline group received saline solution administration 1 
hour after AP induction and PTX group received PTX treatment 1 hour 
after AP induction. Data are expressed as mean ± SEM of 10 animals per 
group.   *p<0.05 comparing sham-operated group with the AP groups; 
p=0.094 comparing PTX and saline groups
PTX effect on lung and pancreatic histology
We also evaluated the severity of pancreatitis by 
histological analysis of lung and pancreatic lesions. Histological 
scores found in animals with AP compared to the sham-operated 
group, did not differ between the PTX and saline treatments after 
AP induction.
PTX effect on mortality study
After AP induction, mortality rate was evaluated. A 
decrease in mortality was observed in the PTX treatment (5/30, 
17%) compared to the saline group (11/30, 37%), (p=0.07) (Figure 
3). There was no mortality in the sham-operated group (data not 
shown).
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FIGURE 3: Animal survival. AP was induced in rats by intraductal 
injection of 0.5ml of 2.5% taurocholic acid. Saline group received saline 
solution administration 1 hour after AP induction and PTX group received 
PTX treatment 1 hour after AP induction.  The Kaplan-Meier curve for 
the two groups is shown. Mortality was observed for 7 days after AP 
induction (p=0.07)
Discussion
Acute pancreatitis involves a complex cascade of events, 
including pancreatic inflammation, destruction of pancreatic 
tissue, and a systemic inflammatory response, mediated by IL-1, 
IL-6, IL-8, TNF-α, NO, reactive oxygen species, and PAF, which 
are markedly increased early after the onset of the disease.
The levels of proinflammatory cytokines seem to 
correlate with morbidity and mortality associated with AP23 .The 
use of drugs that block the activation of these cytokines could 
attenuate the severity of AP. Among these drugs, PTX exhibits 
marked anti-inflammatory properties through the inhibition of 
TNF-α production after shock, acute endotoxemia, and cerebral 
ischemia in rats 11,24,25. The mitogen-activated protein kinases 
(MAPK) and NF-kB are integral components of many signal 
transduction pathways. Hofken et al.26 and De Campos et al.14 have 
demonstrated the role of MAPK activation in AP-induced acute 
lung injury (ALI) with the observations that MAPKs are activated 
early in the course of AP and inhibition of their phosphorylation can 
ameliorate the effects of the disease, indicating that PTX is capable 
of attenuating key signaling events in the inflammatory cascade. 
In addition, they observed a reduction in the phosphorylation of 
cytoplasmic I-kB and nuclear p65-NF-kB, which its activity in both 
the pancreas and distant organs has been shown to correlate with 
degree of illness, whereas inhibitors of NF-kB have been proven 
effective in reducing systemic inflammation in severe AP14,26. 
The suggestion is that PTX regulates cytokines transcription and 
neutrophil recruitment, at least in part, via MAPKs and NF-kB 
signaling pathway.
Treatment of AP with PTX has shown to be beneficial 
in the experimental management of this disease, however 
administration of this drug in these studies was done at the time 
of AP induction13-16. In an experimental model of severe AP, 
evaluating the effect of administration of PTX after the onset of 
AP, no changes of the hemodynamic parameters and mortality rate 
were observed however, in this study inflammatory parameters 
were not evaluated27.
Therefore, in the present study, and according to 
clinical practice, we utilized treatment with PTX after the onset 
of AP and observed reduction of peritoneal and serum levels of 
proinflammatory cytokines.
As has been previously described, TNF-α is considered 
the trigger of an inflammatory cascade in AP because it induces 
the synthesis and release of other cytokines4. Some authors have 
shown the beneficial effect of the pretreatment of AP through 
the inhibition of TNF-α by using an antibody against TNF- α6,7. 
Our group has also demonstrated the beneficial effect o PTX 
administration at the time of AP induction16. In the present study we 
observed that PTX administered after the onset of AP effectively 
inhibited the production of TNF-α and IL-6, which are AP markers 
and whose levels correlate with the severity of the disease. 
Inhibition of TNF-α production, at least in part, via MAPKs and 
NF-kB signaling pathway may explain the marked PTX anti-
inflammatory properties11,24,25. In addition, PTX increases blood 
cell deformability, decreases platelet aggregation, lowers blood 
viscosity, and reduces thrombus formation, therefore improving 
microvascular flow28. In addition, PTX treated rats exhibited a 
prevalence of anti-inflammatory activity compared with the saline 
AP group, as indicated by serum IL-6/IL-10 ratios. The suggestion 
is that the proper production/release of proinflammatory and anti-
inflammatory cytokines might be an importante effect of PTX 
treatment. 
Pulmonary complications are the most critical distant 
event in severe AP, being the most common cause of death during 
the initial phase of the disease29. Previously, it was reported that 
PTX administration at the time of AP induction was capable of 
attenuating pulmonary inflammation and histological lung injury 
in a model of severe AP14. In the present study, we also observed a 
clear tendency to reduction of pulmonary neutrophil sequestration, 
evaluated by MPO levels, in PTX treatment compared to the saline 
group.
Histological scores in lung and pancreas from animals 
with AP, compared to the sham-operated group, did not differ 
between the PTX and saline treatments after AP induction. The drug 
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may be effective however, to ameliorate histological parameters in 
mild edematous pancreatitis (13) or when administration of this 
drug is done at the time of AP induction16.
To further evaluate the effects of PTX treatment, we 
also studied mortality rates after attenuating systemic levels of 
proinflammatory cytokines. The results showed a reduction of 
mortality with PTX treatment compared to the saline group.
In conclusion, this is the first study that demonstrates 
the potential therapeutic effects of PTX administered after severe 
AP induction. Reduction of systemic levels of proinflammatory 
cytokines by this drug might be useful in the clinical practice 
for the management of early phase AP. In fact, clinical studies 
have shown that inflammatory mediators reach the highest 
serum concentration on day three after the onset of AP30. Further 
studies are still needed to fully understand the effects of PTX on 
proinflammatory mediators and other aspects of severe AP. Our 
observations raise the hypothesis that an early therapeutic window 
exits for PTX treatment after the onset of AP, which should be 
object of future studies. 
Acknowledgment: We thank Sandra Sampietre and 
Nilza Molan for technical assistance to this study. 
References
1.  Pitchumoni CS, Patel NM, Shah P: Factors influencing mortality 
in acute pancreatitis: can we alter them? J Clin Gastroenterol. 
2005;39:798-814.
2.  Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 
2008;371:143-52.
3.  Bhatia M, Wong FL, Cao Y, Lau HY, Huang J, Puneet P, Chevali L. 
Pathophysiology of acute pancreatitis. Pancreatology. 2005;5:132-
44.
4.  Norman J. The role of cytokines in the pathogenesis of acute 
pancreatitis. Am J Surg.1998;175:76-83.
5.  Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor 
necrosis factor-alpha in acute pancreatitis: from biological basis to 
clinical evidence. Shock. 2007;28:130-40.
6.  Malleo G, Mazzon E, Genovese T, Di Paola R, Muià C, Centorrino 
T, Siriwardena AK, Cuzzocrea S. Etanercept attenuates the 
development of cerulein-induced acute pancreatitis in mice: a 
comparison with TNF-alpha genetic deletion. Shock. 2007;27:542-
51.
7.  Yilmaz M, Tekekoglu S, Herek O, Ozmen O, Sahinduran S, 
Buyukoglu T Ameliorative effect of adalimumab on experimentally 
induced acute pancreatitis in rats. Pancreas. 2010;39:1238-42.
8.  Machado MC, Coelho AM, Martins JO, Sampietre SN, Molan NA, 
Patzina RA, Machado MA, Jancar S. CO2 abdominal insufflation 
decreases local and systemic inflammatory response in experimental 
acute pancreatitis. Pancreas. 2010;39:175-81.
9.  Souza LJ, Coelho AM, Sampietre SN, Martins JO, Cunha JE, 
Machado MC. Anti-inflammatory effects of peritoneal lavage in 
acute pancreatitis. Pancreas.2010;39:1180-84.
10.  Coelho AM, Jukemura J, Sampietre SN, Martins JO, Molan NA, 
Patzina RA, Lindkvist B, Jancar S, Cunha JE, D’Albuquerque LA, 
Machado MC. Mechanisms of the beneficial effect of hypertonic 
saline solution in acute pancreatitis. Shock. 2010;34:502-7.
11.  Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiestarase 
inhibition on the inflammatory response after shock: role of 
pentoxifylline. J Trauma. 2004;56:442-49.
12.  Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights 
into the regulation of TNF-α production in human mononuclear 
cells: the effects of non-specific phosphodiesterase inhibition. 
Clinics. 2008;63:321-8.
13.  Marton J, Farkas G, Takacs T, Nagy Z, Szasz Z, Varga J,Jarmay 
K, Balogh A, Lonovics J. Beneficial effects of pentoxifylline 
treatment of experimental acute pancreatitis in rats. Res Exp Med. 
1998;197:293-9.
14.  de Campos T, Deree J, Martins JO, Loomis WH, Shenvi E, Putnam 
JG, Loomis WH, Wolf P,. Coimbra R. Pentoxifylline attenuates 
pulmonary inflammation and neutrophil activation in experimental 
acute pancreatitis. Pancreas. 2008;37:42-9.
15.  Sandoval J, Escobar J, Pereda J, Sacilotto N, Rodriguez JL, Sabater 
L, Aparisi L, Franco L, López-Rodas G, Sastre J. Pentoxifylline 
prevents loss of PP2A phosphatase activity and recruitment of 
histone acetyltransferases to proinflammatory genes in acute 
pancreatitis. J Pharmacol Exp Ther. 2009;331:609-7.
16.  Matheus AS, Coelho AM, Sampietre S, Jukemura J, Patzina RA, 
Cunha JE, Machado MC. Do the effects of pentoxifylline on the 
inflammatory process and pancreatic infection justify its use in acute 
pancreatitis? Pancreatology. 2009;9:687-93.
17.  Storck G. Fat necrosis in acute pancreatitis. Morphological and 
chemical studies in the rat. Acta Chir Scand. 1971;417:1-36.
18.  Lankisch PG, Ihse I. Bile-induced acute experimental pancreatitis. 
Scand J Gastroenterol. 1987;22:257-60.
19.  Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure 
of pulmonary leukostasis in rabbits. J Appl Physiol. 1985;59:1978-
85.
20.  Warren JS, Yabroff KR, Mandel DM, Johnson KJ, Ward PA. Role of 
O2- in the neutrophil recruitment into sites of dermal and pulmonary 
vasculitis. Free Radic Biol Med. 1990;8:163-72.
21.  Schmidt J, Rattner DW, Lewandrowski R, Compton CC, Mandavilli 
U, Knoefel WT, Warshaw AL. A better model of acute pancreatitis 
for evaluating therapy. Ann Surg. 1992;215:44-56.
22.  Simons RK, Maier RV, Chi EY. Pulmonary effects of continuous 
endotoxin infusion in the rat. Circ Shock. 1991;33:233-43.
23.  Hirota M, Nozawa F, Okabe A, Shibata M, Beppu T, Shimada S, 
Egami H, Yamaguchi Y, Ikei S, Okajima T, Okamoto K, Ogawa. 
Relationship between plasma cytokine concentration and multiple 
organ failure in patients with acute pancreatitis. Pancreas. 
2000;21:141-6.
24.  Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB. 
Phosphodiesterase inhibition decreases nuclear factor-kappaB 
activation and shifts the cytokine response toward anti-inflammatory 
activity in acute endotoxemia. J Trauma . 2005;9:575-82.
25.  Vakili A, Mojarrad S, Akhavan MM, Rashidy-Pour A. Pentoxifylline 
attenuates TNF-α protein levels and brain edema following temporary 
focal cerebral ischemia in rats. Brain Res. 2011;1377:119-25.
26.  Hofken T, Keller N, Fleischer F, Göke B, Wagner AC. Map kinase 
phosphatases (MKP´s) are early responsive genes during induction 
of cerulein hyperstimulation pancreatitis. Biochem Biophys Res 
Commun. 2000;276:680-5.
27.  Bassi DG, Foitzik T, Rattner DW, Lewandrowski K, Warshaw AL, 
Fernández-del Castillo C. Failure of pentoxifylline to ameliorate 
severe acute pancreatitis in the rat: results of a prospective, 
randomized, controlled study. Crit Care Med. 1994;22:1960-3.
28.  Huh PW, Kotasek D, Jacob HS, Vercellotti GM, Hammerschmidt 
DE. Mechanism of action of pentoxifylline in peripheral vascular 
Is there a therapeutic window for pentoxifylline after the onset of acute pancreatitis?
Acta Cirúrgica Brasileira - Vol. 27 (7) 2012 - 493
disease: inhibition of platelet and granulocyte responsiveness. Clin 
Res. 1985;33:866-78.
29.  Zhou MT, Chen CS, Chen BC, Zhang QY, Andersson R. Acute lung 
injury and ARDS in acute pancreatitis: mechanisms and potential 
intervention. World J Gastroenterol. 2010;16:2094-9. 
30.  Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators 
in human acute pancreatitis: clinical and pathophysiological 
implications. Gut. 2000;47:546-52. 
Correspondence
Ana Maria Mendonça Coelho
Departmento de Gastroenterologia
Universidade de São Paulo
R. João Moura, 690/41
05412-001 São Paulo, SP, Brazil
Tel(5511)3061-8326, FAX(5511) 3061-7270
amcoelho@usp.br
Received: February 16, 2012
Review: April 18, 2012
Accepted: May 21, 2012
Conflict of interest: none
Financial source: São Paulo Research Foundation (FAPESP)
1Research performed at Laboratory of Liver Transplantation and 
Experimental Surgery (LIM/37), Department of Gastroenterology, 
Medical School, University of São Paulo, São Paulo, Brazil 
